187 related articles for article (PubMed ID: 22050015)
1. Role of bacillus Calmette-Guérin in the treatment of advanced melanoma.
Stewart JH; Levine EA
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1671-6. PubMed ID: 22050015
[TBL] [Abstract][Full Text] [Related]
2. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular insights into BCG immunotherapy for melanoma.
Kremenovic M; Schenk M; Lee DJ
J Intern Med; 2020 Dec; 288(6):625-640. PubMed ID: 32128919
[TBL] [Abstract][Full Text] [Related]
4. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma.
Tan JK; Ho VC
J Dermatol Surg Oncol; 1993 Nov; 19(11):985-90. PubMed ID: 8245304
[TBL] [Abstract][Full Text] [Related]
5. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
6. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
7. Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments.
Nishida S; Tsuboi A; Tanemura A; Ito T; Nakajima H; Shirakata T; Morimoto S; Fujiki F; Hosen N; Oji Y; Kumanogoh A; Kawase I; Oka Y; Azuma I; Morita S; Sugiyama H
Medicine (Baltimore); 2019 Aug; 98(33):e16771. PubMed ID: 31415377
[TBL] [Abstract][Full Text] [Related]
8. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
9. 5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guérin with epirubicin and interferon-α2b in patients with T1 bladder cancer.
Hemdan T; Johansson R; Jahnson S; Hellström P; Tasdemir I; Malmström PU;
J Urol; 2014 May; 191(5):1244-9. PubMed ID: 24231843
[TBL] [Abstract][Full Text] [Related]
10. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
12. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
13. Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities.
Ariyan S; Kirkwood JM; Mitchell MS; Nordlund JJ; Lerner AB; Papac RJ
Surgery; 1982 Sep; 92(3):459-63. PubMed ID: 7112396
[TBL] [Abstract][Full Text] [Related]
14. Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer.
Guinan P; Toronchi E; Shaw M; Crispin R; Sharifi R
Urology; 1982 Oct; 20(4):401-3. PubMed ID: 6755855
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis.
Boehm BE; Cornell JE; Wang H; Mukherjee N; Oppenheimer JS; Svatek RS
J Urol; 2017 Sep; 198(3):503-510. PubMed ID: 28286068
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of melanoma-associated antigens detected by sera from patients receiving adjuvant allogeneic tumor vaccine immunotherapy.
Dent PB; McCulloch PB; Liao SK; Stone BR; Singal DP
Clin Immunol Immunopathol; 1982 May; 23(2):379-91. PubMed ID: 6980756
[No Abstract] [Full Text] [Related]
17. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin.
Grant SC; Kris MG; Houghton AN; Chapman PB
Clin Cancer Res; 1999 Jun; 5(6):1319-23. PubMed ID: 10389914
[TBL] [Abstract][Full Text] [Related]
18. Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer.
Sfakianos JP; Salome B; Daza J; Farkas A; Bhardwaj N; Horowitz A
Urol Oncol; 2021 Feb; 39(2):121-129. PubMed ID: 33262028
[TBL] [Abstract][Full Text] [Related]
19. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.
Krege S; Giani G; Meyer R; Otto T; Rübben H
J Urol; 1996 Sep; 156(3):962-6. PubMed ID: 8709374
[TBL] [Abstract][Full Text] [Related]
20. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
